Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
- Johnson & Johnson reported Phase 2 nipocalimab data on symptoms valued by people with Sjögren's disease.
- Mouth dryness was the most important symptom improvement and was reported by 96% of surveyed patients.
- Other frequently reported symptoms included fatigue, eye dryness, joint pain, and, among women, vaginal dryness.
- Interviewed patients reported improvements associated with better physical functioning, easier disease management, and less disruption to daily commitments.
16 Articles
16 Articles
The Courier-Tribune
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint painPatient insights complement Phase 2 study results demonstrating a 50% increase…
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients - PressReach
New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more than twice as many patients on nipocalimab compared to placeboc Two … Continue reading "Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögre…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
